{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T19:00:45Z","timestamp":1789585245483,"version":"build-2803163510"},"reference-count":19,"publisher":"BMJ","issue":"5","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Arch Dis Child"],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Burosumab, an antifibroblast growth factor 23 monoclonal antibody, improves rickets severity, symptoms and growth in children with X-linked hypophosphataemia (XLH) followed up to 64 weeks in clinical trials. International dosing guidance recommends targeting normal serum phosphate concentration; however, some children may not achieve this despite maximal dosing. This study compares clinical outcomes in children with XLH on long-term burosumab treatment who achieved normal phosphate versus those who did not.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Single-centre retrospective review of a large paediatric cohort with XLH treated with burosumab. We evaluated growth and biochemical markers of bone health in those who did compared with those who did not achieve normal plasma phosphate concentration.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Fifty-five children with XLH with median age of 11.7 (IQR 6.8\u201315.5) years were included. 27 (49%) had low plasma phosphate concentration, and 27 (49%) had normal phosphate after a median burosumab treatment duration of 3.3 (IQR 2.6\u20133.7) years. 1 (2%) did not have a recent phosphate level recorded. No difference in growth was found between normal and abnormal phosphate groups (p=0.9).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Young children with XLH experience sustained growth on long-term burosumab treatment, although without normal plasma phosphate concentration in many. Consideration should be made to changing burosumab dosing recommendations to target normalisation of alkaline phosphatase, as opposed to plasma phosphate concentration.<\/jats:p><\/jats:sec>","DOI":"10.1136\/archdischild-2022-324962","type":"journal-article","created":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T18:20:50Z","timestamp":1675102850000},"page":"379-384","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":20,"title":["Burosumab in management of X-linked hypophosphataemia: a retrospective cohort study of growth and serum phosphate levels"],"prefix":"10.1136","volume":"108","author":[{"given":"Emma Yi Xiu","family":"Walker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy Alexander James","family":"Lindsay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0858-7064","authenticated-orcid":false,"given":"Jeremy","family":"Allgrove","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matko","family":"Marlais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Detlef","family":"Bockenhauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8091-6945","authenticated-orcid":false,"given":"Wesley","family":"Hayes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,1,30]]},"reference":[{"key":"2023100301251371000_108.5.379.1","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s00467-011-2046-z","article-title":"Growth in PHEX-associated X-linked hypophosphatemic rickets: the importance of early treatment","volume":"27","author":"Quinlan","year":"2012","journal-title":"Pediatr Nephrol"},{"key":"2023100301251371000_108.5.379.2","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.340"},{"key":"2023100301251371000_108.5.379.3","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-020-01434-4","article-title":"The International X-linked hypophosphataemia (XLH) registry (NCT03193476): rationale for and description of an international, observational study","volume":"15","author":"Padidela","year":"2020","journal-title":"Orphanet J Rare Dis"},{"key":"2023100301251371000_108.5.379.4","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1210\/js.2018-00365","article-title":"The lifelong impact of X-linked hypophosphatemia: results from a burden of disease survey","volume":"3","author":"Skrinar","year":"2019","journal-title":"J Endocr Soc"},{"key":"2023100301251371000_108.5.379.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198010303031802"},{"key":"2023100301251371000_108.5.379.6","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1056\/NEJMoa1714641","article-title":"Burosumab therapy in children with X-linked hypophosphatemia","volume":"378","author":"Carpenter","year":"2018","journal-title":"N Engl J Med"},{"key":"2023100301251371000_108.5.379.7","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1016\/S0140-6736(19)30654-3","article-title":"Burosumab versus conventional therapy in children with X-linked Hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial","volume":"393","author":"Imel","year":"2019","journal-title":"Lancet"},{"key":"2023100301251371000_108.5.379.8","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S2213-8587(18)30338-3","article-title":"Efficacy and safety of burosumab in children aged 1-4 years with X-linked Hypophosphataemia: a multicentre, open-label, phase 2 trial","volume":"7","author":"Whyte","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2023100301251371000_108.5.379.9","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2020.00338","article-title":"Clinical evidence for the benefits of Burosumab therapy for X-linked hypophosphatemia (XLH) and other conditions in adults and children","volume":"11","author":"Schindeler","year":"2020","journal-title":"Front Endocrinol"},{"key":"2023100301251371000_108.5.379.10","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3389\/fped.2020.00048","article-title":"Positive response to one-year treatment with Burosumab in pediatric patients with X-linked hypophosphatemia","volume":"8","author":"Mart\u00edn Ramos","year":"2020","journal-title":"Front Pediatr"},{"key":"2023100301251371000_108.5.379.11","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1210\/clinem\/dgab729","article-title":"Sustained efficacy and safety of Burosumab, a monoclonal antibody to FGF23, in children with X-linked hypophosphatemia","volume":"107","author":"Linglart","year":"2022","journal-title":"J Clin Endocrinol Metabolism"},{"key":"2023100301251371000_108.5.379.12","unstructured":"European Medicines Agency . Crysvita EPAR product information. Summary of product characteristics. Available: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/crysvita-epar-product-information_en.pdf [Accessed 31 Jul 2022]."},{"key":"2023100301251371000_108.5.379.13","unstructured":"US Food and Drug Administration . Crysvita (prescribing information). Available: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/761068s000lbl.pdf [Accessed 31 Jul 2022]."},{"key":"2023100301251371000_108.5.379.14","doi-asserted-by":"publisher","DOI":"10.1038\/S41581-019-0152-5"},{"key":"2023100301251371000_108.5.379.15","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/s41574-022-00662-x","article-title":"Interdisciplinary management of FGF23-related phosphate wasting syndromes: a consensus statement on the evaluation, diagnosis and care of patients with X-linked hypophosphataemia","volume":"18","author":"Trombetti","year":"2022","journal-title":"Nat Rev Endocrinol"},{"key":"2023100301251371000_108.5.379.16","unstructured":"World Health organization Anthro survey analyser and other tools. Available: https:\/\/www.who.int\/tools\/child-growth-standards\/software [Accessed 31 Jul 2022]."},{"key":"2023100301251371000_108.5.379.17","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1093\/clinchem\/34.8.1622","article-title":"Age- and sex-specific pediatric reference intervals for biochemistry analytes as measured with the Ektachem-700 analyzer","volume":"34","author":"Lockitch","year":"1988","journal-title":"Clin Chem"},{"key":"2023100301251371000_108.5.379.18","doi-asserted-by":"publisher","DOI":"10.1177\/000456329803500203"},{"key":"2023100301251371000_108.5.379.19","doi-asserted-by":"crossref","first-page":"e3241","DOI":"10.1210\/clinem\/dgac296","article-title":"Effect of Burosumab compared with conventional therapy on younger vs older children with X-linked hypophosphatemia","volume":"107","author":"Ward","year":"2022","journal-title":"J Clin Endocrinol Metabolism"}],"container-title":["Archives of Disease in Childhood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/archdischild-2022-324962","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T08:29:24Z","timestamp":1696321764000},"score":1,"resource":{"primary":{"URL":"https:\/\/adc.bmj.com\/lookup\/doi\/10.1136\/archdischild-2022-324962"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,30]]},"references-count":19,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,4,19]]},"published-print":{"date-parts":[[2023,5]]}},"alternative-id":["10.1136\/archdischild-2022-324962"],"URL":"https:\/\/doi.org\/10.1136\/archdischild-2022-324962","relation":{},"ISSN":["0003-9888","1468-2044"],"issn-type":[{"value":"0003-9888","type":"print"},{"value":"1468-2044","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,30]]}}}